Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (461-470 of 471) with videos related to

Pageof 48
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2023
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple MyelomaJulia E Wiedmeier-Nutor, Madiha Iqbal, Allison C Rosenthal, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
American Journal of Hematology|June 9, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating AgentsSaubia Fathima, Margaret Mei-Kay Wong, Jesus Gonzalez-Lugo, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Pageof 48

Showing results (461-470 of 471) with videos related to

Sort By:
Pageof 48
Clinical Lymphoma, Myeloma & Leukemia|April 1, 2023
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple MyelomaJulia E Wiedmeier-Nutor, Madiha Iqbal, Allison C Rosenthal, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
American Journal of Hematology|June 9, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating AgentsSaubia Fathima, Margaret Mei-Kay Wong, Jesus Gonzalez-Lugo, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Pageof 48